title: Hemolytic uremic syndrome presenting after treatment of endodermal sinus tumor.
abstract: BACKGROUND
  Hemolytic uremic syndrome is a rare multisystem disorder that is caused by infections, preeclampsia, autoimmune disorders, or oral contraceptive agents, and rarely in association with different cancers and chemotherapeutic agents.
  
  
  METHODS
  A 34-year-old woman who presented for evaluation of a pelvic mass received a diagnosis of International Federation of Gynecology and Obstetrics (FIGO) stage 1c endodermal sinus tumor at laparotomy. Three months after receiving 3 courses of bleomycin, etoposide, and cisplatinum, she presented with renal failure, thrombocytopenia, anemia, and severe hypertension. Cancer-associated hemolytic uremic syndrome was diagnosed, and the patient was treated with plasmaphoresis, blood transfusion, and hemodialysis.
  
  
  CONCLUSIONS
  Cancer-associated hemolytic uremic syndrome has a high mortality rate; thus, prompt diagnosis is critical to survival.
authors.affiliation: Department of Obstetrics and Gynecology, Good Samaritan Hospital, Cincinnati, Ohio, USA.
authors.forename: Dele A
authors.initials: DA
authors.lastname: Ogunleye
authors.forename: Sharyn N
authors.initials: SN
authors.lastname: Lewin
authors.forename: David G
authors.initials: DG
authors.lastname: Mutch
authors.forename: Helen
authors.initials: H
authors.lastname: Liapis
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Herzog
mesh_terms: D015746:Abdominal Pain / Q000175:diagnosis / Q000209:etiology; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001707:Biopsy, Needle; D001803:Blood Transfusion; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003131:Combined Modality Therapy; D018240:Endodermal Sinus Tumor / Q000473:pathology* / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D007150:Immunohistochemistry; D010051:Ovarian Neoplasms / Q000473:pathology* / Q000628:therapy*; D010052:Ovariectomy / Q000379:methods; D010956:Plasmapheresis; D006435:Renal Dialysis; D018570:Risk Assessment; D016896:Treatment Outcome